Royalty Reduction. In the event that a Third Party markets, for the same indication as a Licensed Product, a product containing or comprising a Peripheral Compound or an SAR Compound (as “Peripheral Compound” and “SAR Compound” are defined in the Lilly Agreement rather than in this Agreement) of the GenuPro Compound and such Third Party is Lilly or acquired rights to such compound from Lilly, then the rate at which Licensee is obligated to pay royalties to GenuPro with respect to such Licensed Product under Section 5.03 shall be reduced [*] during the time that such Third Party is marketing such product. [*] Confidential treatment requested; certain information omitted and filed separately with the SEC.
Appears in 6 contracts
Samples: License Agreement (Furiex Pharmaceuticals, Inc.), License Agreement (Furiex Pharmaceuticals, Inc.), License Agreement (Furiex Pharmaceuticals, Inc.)
